Mirae Asset Global Investments Co. Ltd. trimmed its holdings in shares of BioNTech SE (NASDAQ:BNTX – Get Rating) by 11.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 20,480 shares of the company’s stock after selling 2,619 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in BioNTech were worth $3,494,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the business. B. Metzler seel. Sohn & Co. AG boosted its stake in BioNTech by 483.0% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 14,545 shares of the company’s stock valued at $2,481,000 after purchasing an additional 12,050 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of BioNTech in the 1st quarter worth $283,000. Edmond DE Rothschild Holding S.A. boosted its stake in shares of BioNTech by 16.2% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 1,077 shares of the company’s stock worth $183,000 after buying an additional 150 shares during the last quarter. Advisors Capital Management LLC boosted its stake in shares of BioNTech by 3.2% in the 1st quarter. Advisors Capital Management LLC now owns 26,636 shares of the company’s stock worth $4,543,000 after buying an additional 833 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of BioNTech by 89,660.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,488 shares of the company’s stock worth $765,000 after buying an additional 4,483 shares during the last quarter. 14.42% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. set a $183.00 price target on BioNTech in a research note on Tuesday, May 10th. Cowen started coverage on BioNTech in a research note on Wednesday, August 17th. They set a “market perform” rating and a $177.00 price objective on the stock. UBS Group set a $168.00 target price on BioNTech in a research report on Thursday, June 30th. TheStreet upgraded BioNTech from a “d+” rating to a “c-” rating in a research report on Wednesday, May 4th. Finally, HC Wainwright lowered their price target on BioNTech from $283.00 to $272.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $231.43.
BioNTech Stock Performance
Shares of BNTX stock opened at $147.25 on Wednesday. The business’s fifty day simple moving average is $155.15 and its 200-day simple moving average is $156.50. The company has a market cap of $35.74 billion, a PE ratio of 2.84 and a beta of -0.08. The company has a current ratio of 5.15, a quick ratio of 5.06 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12-month low of $117.08 and a 12-month high of $379.98.
BioNTech (NASDAQ:BNTX – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported $6.45 EPS for the quarter, missing the consensus estimate of $7.08 by ($0.63). BioNTech had a net margin of 55.43% and a return on equity of 88.76%. The business had revenue of $3.20 billion during the quarter, compared to analysts’ expectations of $4.11 billion. During the same period in the previous year, the company posted $12.98 earnings per share. BioNTech’s revenue for the quarter was down 39.8% compared to the same quarter last year. Analysts expect that BioNTech SE will post 33.37 earnings per share for the current fiscal year.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
Receive News & Ratings for BioNTech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioNTech and related companies with MarketBeat.com’s FREE daily email newsletter.